Ask about this productRelated genes to: Reck antibody
- Gene:
- RECK NIH gene
- Name:
- reversion inducing cysteine rich protein with kazal motifs
- Previous symbol:
- ST15
- Synonyms:
- hRECK
- Chromosome:
- 9p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-10-30
- Date modifiied:
- 2016-01-28
Related products to: Reck antibody
Related articles to: Reck antibody
- Precision oncology has changed the management of advanced non-small-cell lung cancer (NSCLC). Biomarker-matched therapies now improve outcomes in an increasing number of molecularly defined subgroups. In this second paper in a Series on therapeutics in lung cancer, we summarise recent advances in NSCLC with established alterations, including EGFR, ALK, ROS1, KRAS, BRAF, RET, HER2, MET, and NTRK, and discuss emerging targets, such as NRG1 fusions, MTAP loss, and SMARCA4 deficiency. Newer generations of tyrosine kinase inhibitors, the introduction of bispecific antibodies, and antibody-drug conjugates have improved response durability, intracranial disease control, and in some settings, overall survival. However, durable benefit can remain limited by acquired resistance, tumour heterogeneity, lineage plasticity, and off-target escape, supporting repeat tissue biopsy and circulating-tumour DNA profiling to guide subsequent treatment. With several options available such as monotherapy and combination approaches, individualised treatment selection is becoming increasingly complex. We discuss these choices, including the management of CNS disease and oligoprogression, and long-term tolerability. As drug development extends beyond canonical drivers to rarer alterations and adverse co-mutations, the range of targetable disease is increasing. Further progress will depend on more effective and adaptive treatment strategies together with equitable access to comprehensive molecular profiling, timely biomarker testing, and next-generation targeted therapies. - Source: PubMed
Publication date: 2026/09/06
Hendriks Lizza E LLin Jessica JTan Daniel S WAcker FabianOgliari Francesca RMeyer May-LuciePlanchard DavidReck Martin - To assess outcomes with perioperative durvalumab by type of surgery in patients with resectable non-small cell lung cancer (NSCLC) from the AEGEAN study. - Source: PubMed
Publication date: 2026/09/03
Harpole DavidHeymach John VReck MartinTaube JanisGao ShugengLi GaofengYou JianVan Luong DinhSaeteng SomcharoenDoake RuthFouad Tamer MMitsudomi Tetsuya - Seafarers are exposed to unique occupational stressors that place sustained demands on the autonomic nervous system. Heart rate variability (HRV) represents a promising non-invasive tool for assessing mental and physical strain in maritime settings. However, its methodological application in real field conditions remains poorly characterized, and existing HRV guidelines do not specifically address the methodological challenges of maritime field studies. - Source: PubMed
Publication date: 2026/08/21
Vasylenko DanielScheit LorenzReck ChiaraDengler DorotheeHarth VolkerOldenburg Marcus - To characterise the clinical and genetic profile of adult familial Mediterranean fever (FMF) patients at a German tertiary referral centre and examine genotype-phenotype associations. - Source: PubMed
Publication date: 2026/08/28
Reck DorotheaHenes Jörg ChristophSaur Sebastian Jonas - In AEGEAN, perioperative durvalumab plus neoadjuvant chemotherapy, versus neoadjuvant chemotherapy alone, significantly improved event-free survival (EFS) and pathologic complete response in patients with resectable non-small cell lung cancer (R-NSCLC), with a safety profile consistent with the individual agents. We report EFS from a second planned interim analysis, interim disease-free survival (DFS) and overall survival (OS), and safety, after all patients completed/discontinued treatment. In this phase III, double-blind, placebo-controlled study, patients with treatment-naïve R-NSCLC (stage II-IIIB [N2]) were randomly assigned (1:1) to neoadjuvant platinum-based chemotherapy plus durvalumab/placebo (once every 3 weeks, four cycles) presurgery and then adjuvant durvalumab/placebo (once every 4 weeks, 12 cycles). Efficacy was analyzed in the modified intention-to-treat population (n = 740; for DFS, its resected subpopulation), which excluded patients with documented / aberrations. As of May 10, 2024 (median follow-up, 25.9 months [censored patients]), EFS benefit favoring the durvalumab arm remained consistent (hazard ratio [HR], 0.69 [95% CI, 0.55 to 0.88]). Numerical improvement in DFS (HR, 0.66 [95% CI, 0.47 to 0.92]) and OS (HR, 0.89 [95% CI, 0.70 to 1.14]) favored the durvalumab arm. Maximum grade 3/4 adverse events occurred in 15.4% and 10.6% of the durvalumab and placebo arms, respectively, during adjuvant treatment. These results further support perioperative durvalumab plus neoadjuvant chemotherapy as a new treatment option. - Source: PubMed
Publication date: 2026/08/28
Heymach John VHe JieHarpole DavidMitsudomi TetsuyaTaube Janis MGao ShugengUrban LaszloKang Jin HyoungOrlandi Francisco JRodriguez-Cid JeronimoMassuti BartomeuMateos Luis LeonPasello GiuliaChu QuincyKolb-Sielecki JaroslawNakata MasaoGalffy GabriellaHochmair MaximilianWinder ThomasZukov RuslanGarbaos GabrielHorio YoshitsuguOstoros GyulaTran Tho VYou JianLee Kang-YunAntonuzzo LorenzoAkamatsu HiroakiBiswas BivasSpira AlexanderCrawford JeffreyLe Ha TAperghis MikeMann HelenFouad Tamer MDoherty Gary JReck Martin